Skip to main content
Equibles
CHRS logo

CHRS · Coherus Oncology, Inc.

Track CHRS — free

Use CHRS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.41 -0.05 (-3.42%) At close · Aug 28
Russell 2000 member Rebalance outlook locked
Market Cap
$217.85M
Shares
154.50M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.41 Open$1.45 Day$1.40–1.48 52W close$1.10–2.51 Avg vol 30d1.0M Short int24.0M · 15.5% float · 19.7d Short vol33% Last earningsAug 5, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 2, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 14.4 · calm Equity put/call 0.62
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −10%
      below
      Price vs 50-day avg −0%
      below
      RSI (14) 53
      neutral
      MACD trend Positive
      52-week position 22%
      mid-range
      Momentum
      relative strength
      Weak
      1-month return 0%
      trailing
      6-month return −27%
      trailing
      YTD return −1%
      this year
      Relative strength −40%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Distributing
      -7% holders QoQ · +11 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      15.53% of float · ▼ -2.2% MoM · 19.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      147 holders — mid 3-yr range
      Squeeze score 72
      high risk · 0–100
      Fundamentals
      Fair
      Revenue growth −100%
      Y/Y
      EPS growth +472%
      Y/Y
      Free cash flow $-138.8M
      Balance sheet $104.0M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 81%
      annualized · 1-yr
      Max drawdown −55%
      past year
      ATR 6.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the Earnings Call filed Jun 30, 2026
      Combined OpEx · full year 2026 Initiated $170M – $175M
      Prior guidance period ended · from the Earnings Call filed Mar 31, 2024
      Combined R&D and SG&A expenses · 2024 $250M – $265M
      Guided vs delivered · last 1 settled
      Net sales full year 2023
      guided at least $275M
      $1.22M Miss −99.6%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −10% Bearish
      Price vs 50-day avg
      −0% Neutral
      RSI (14)
      53 Neutral
      MACD trend
      Positive Bullish
      52-week position
      22% Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Distributing
      -7% holders QoQ · +11 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      15.53% of float · ▼ -2.2% MoM · 19.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      147 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $1 Now $1 · 22% Range high $3
      vs 200-day avg -10% vs 50-day avg 0%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      GAAP → non-GAAP reconciliation
      GAAP GAAP net loss from continuing operations -$36.94M
      +$2.39M Stock-based compensation expense
      +$0K Change in fair value of Royalty Fee Derivative Liability
      +$625K Amortization of intangible assets
      = Non-GAAP net loss from continuing operations -$33.93M
      Cash, cash equivalents and marketable securities $172.1M as of December 31, 2025 —
      Secured and convertible debt $38.8M as of December 31, 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      CHRS
      Coherus Oncology, Inc.
      this stock
      		$217.85M -0.7% -100.0% — 15.5%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $137.30B +19.5% +46.2% 31.6 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $81.77B +2.9% +20.8% 19.7 2.3%
      ARGX
      Argenx SE
      		 $63.63B +21.7% — — 1.9%
      CSLLY
      Csl Ltd
      		 $59.23B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      147
      % held
      45.6%
      Net QoQ
      -1.4M sh
      Top holder
      Timothy G. Youngquist 202…
      Held Float
      View
      Held by Funds
      Fund positions
      127
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      24.0M
      Days to cover
      19.7d
      Change
      -529.8K sh
      View
      Short Volume
      Short vol %
      33%
      As of
      Aug 28, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      2.9K
      Value
      $4.2K
      As of
      Jul 29, 2026
      View
      Off-Exchange
      Off-exchange %
      46.7%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Shri Thanedar
      Amount
      $15.0K–$50.0K
      Traded
      Jan 23, 2023
      View
      Financials
      Financials
      Revenue (FY)
      $0
      Net income (FY)
      $168.0M
      EPS diluted
      $1.43
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 28, 2026
      This year
      17
      View
      Proposed Sales
      Value
      $449.8K
      Shares
      223.1K
      Filed
      Nov 22, 2023
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 5, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      CHRS -0.7% +0.0% -26.9% +0.0% -0.7%
      SPY +0.5% +3.0% +13.4% +3.0% +12.8%
      vs SPY -1.2% -3.0% -40.4% -3.0% -13.5%
      Key facts CIK 1512762 CUSIP 19249H103 13F (30d) 123 filings 121 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)